Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Data to be Presented at the 7th International ... Symposium on Uveitis ... a leading,developer of antibody fragment therapeutics, today announced that the,company ... lead product candidate, ESBA105, in ophthalmic indications. In,April 2008, ESBATech ...
... DNA TESTING FOR $59.95, THE MOST AFFORDABLE PRICING AVAILABLE ... ... Sept. 8 Familybuilder today announces from,the DEMOfall 08 conference here ... http://www.familybuilder.com ) and the introduction of $59.95 DNA tests,the most ...
... NOCC Spokesperson, Eva La Rue, Lends Her Support as, ... Ovarian Cancer -, LOS ANGELES, Sept. 6 ... national haircare and styling partner,is hosting the first annual ... Cancer" at Dockweiler Beach in Playa del Ray, CA. ...
Cached Biology Technology:ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 2Familybuilder Launches the Familybuilder Global Network at DEMOfall 08 3National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer' 2National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer' 3
(Date:4/24/2014)... Ind. - Purdue and West Virginia University researchers are ... eagle, providing a bird,s-eye view of eagle features that ... Their study calls into question long-held assumptions about golden ... as sensitive to ultraviolet light as previously thought. The ... sharper sense of smell than researchers realized. , ...
(Date:4/24/2014)... Rochelle, NY, April 24, 2014D-ribose is a commercially ... supplement, and as a starting compound for synthesizing ... Escherichia coli to increase the bacteria,s ... toward achieving more efficient industrial-scale production of this ... Industrial Biotechnology , a peer-reviewed journal from ...
(Date:4/24/2014)... have invented a simple and cheap way of making ... into a high-resolution microscope. , Costing less than a ... medicine in developing countries and remote areas. , The ... from The Australian National University (ANU) Research School of ... Garvan Institute of Medical Research to find ways to ...
Breaking Biology News(10 mins):Genome yields insights into golden eagle vision, smell 2Droplet lens 2
... enables rice to survive complete submergence has beenidentified ... RiceResearch Institute in the Philippines and at the ... allows fordevelopment of new rice varieties that can ... and offering reliefto millions of poor rice farmers ...
... alien species have invaded, they usually find predictable patterns. ... in natural processes such as nutrient cycling, wildfire frequency ... , But simply observing such changes doesn't prove that ... researchers Emily Farrer and Deborah Goldberg, however, came up ...
... time in as many months, the IODP Arctic Coring Expedition ... In the Aug. 10 issue of Nature, an article by ... that the Arctic was extremely warm, unusually wet, and ice-free ... gases were released into the Earth's atmosphere ?a period calculated ...
Cached Biology News:New flood-tolerant rice offers relief for world's poorest farmers 2New flood-tolerant rice offers relief for world's poorest farmers 3Invasive species alter habitat to their benefit 2Invasive species alter habitat to their benefit 3Arctic coring expedition continues to yield new clues 2
Ezrin/Radixin/Moesin Antibody...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
... Rabbit polyclonal to ADAMTS16 ( Abpromise ... Antigen: Synthetic peptide ... human ADAMTS-16. Note: the amino acid ... Entrez GeneID: 170690 ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: